Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2024-04-25 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "成都欧康医药股份有限公司 2024 年第一季度报告" which translates to "Chengdu Oukang Pharmaceutical Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the period ending March 31, 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the first quarter of 2024. It is unaudited but contains substantive financial data and management commentary. This matches the definition of an Interim / Quarterly Report (IR). The document length is about 15,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-25 Chinese
第三届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 24th meeting of the third board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting's attendance, procedures, and the approval of the 2024 first quarter report. It references the actual quarterly report which was disclosed separately on April 26, 2024, on the Beijing Stock Exchange information platform. The document itself does not contain the financial data or the full quarterly report but is a formal announcement of the board meeting decisions. Therefore, it is a Board/Management Information announcement rather than the actual Interim/Quarterly Report or Earnings Release.
2024-04-25 Chinese
2023年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2023 Annual Report. It references the 2023 Annual Report and its summary, which were previously disclosed, and invites investors to participate in an online meeting to discuss the annual report results. The document does not contain the annual report itself or detailed financial data, but rather announces the upcoming event to explain the annual report. The document length is short (1160 characters), and it serves as an announcement rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R), as it is a presentation and material shared during an annual meeting context, specifically an annual report performance explanation meeting.
2024-04-23 Chinese
申万宏源证券承销保荐有限责任公司关于成都欧康医药股份有限公司关联担保暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities underwriting and sponsorship company regarding the verification of related party guarantees and related transactions for Chengdu Oukang Pharmaceutical Co., Ltd. It includes comprehensive information about credit limits, guarantees, related party transactions, board and supervisory committee approvals, and the impact on the company and shareholders. The document references specific meetings, voting results, and regulatory compliance, indicating it is a formal verification or audit-type report rather than a simple announcement or presentation. The length is 3740 characters, which is relatively short but contains substantive content about the related party transactions and guarantees, including legal and regulatory compliance. It is not an annual report, earnings release, or management discussion but rather a formal audit or verification report on related party transactions and guarantees. Therefore, the most appropriate classification is Audit Report / Information (AR).
2024-04-18 Chinese
董事、监事换届公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's board of directors and supervisory board members. It details the nomination and appointment of new directors and supervisors, their qualifications, and the compliance with relevant laws and company regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on management changes and governance structure updates. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3435 characters, which is consistent with a detailed announcement rather than a full report.
2024-04-16 Chinese
独立董事候选人声明与承诺（赵宇霆）
Regulatory Filings Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for Chengdu Oukang Pharmaceutical Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and commitment to independence and duties. There is no financial data, no report or announcement of financial results, no voting results, no management changes, or other typical financial or regulatory filings. It is a regulatory compliance statement related to board candidate qualifications. This type of document does not fit into financial reports or announcements but is a regulatory filing related to governance and compliance. Therefore, the best classification is Regulatory Filings (RNS). The document length is short and focused on a compliance declaration, not a report or announcement of a report.
2024-04-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.